Global Nucleic Acid-based Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Nucleic Acid-based Therapeutics Market Growth (Status and Outlook) 2023-2029

Gene therapy is a technique for correcting defective genes responsible for disease development. Nucleic acid-based molecules (deoxyribonucleic acid, complementary deoxyribonucleic acid, complete genes, ribonucleic acid, and oligonucleotides) are utilized as research tools within the broad borders of gene therapy and the emerging field of molecular medicine.

LPI (LP Information)' newest research report, the “Nucleic Acid-based Therapeutics Industry Forecast” looks at past sales and reviews total world Nucleic Acid-based Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Nucleic Acid-based Therapeutics sales for 2023 through 2029. With Nucleic Acid-based Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleic Acid-based Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Nucleic Acid-based Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nucleic Acid-based Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nucleic Acid-based Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleic Acid-based Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleic Acid-based Therapeutics.

The global Nucleic Acid-based Therapeutics market size is projected to grow from US$ 513.5 million in 2022 to US$ 677.7 million in 2029; it is expected to grow at a CAGR of 4.0% from 2023 to 2029.

Although most of the nucleic acid-based drugs are in early stages of clinical trials, these classes of compounds have emerged in recent years to yield extremely promising candidates for drug therapy to a wide range of diseases, including cancer, infectious diseases, diabetes, cardiovascular, inflammatory, and neurodegenerative diseases, cystic fibrosis, hemophilia, and other genetic disorders.

This report presents a comprehensive overview, market shares, and growth opportunities of Nucleic Acid-based Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Anti-Sense And Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers

Segmentation by application
Hospitals
Academic & Research Institutes

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Wave Life Sciences
Imugene
Caperna
Phylogica
Protagonist Therapeutics
Benitec Biopharma
EGEN
BioMedica
Transgene
Copernicus Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.